Reported results
- Research and development expenses were $38.2 million for the third quarter of 2026.
- Net loss was $44.3 million for the third quarter of 2026.
- Total revenue was $0 for the third quarter of 2026.
- General and administrative expenses were $3.7 million for the third quarter of 2026.
- Cash and cash equivalents were $107.9 million as of September 30, 2026.
Guidance
- Spero expects its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures into the second half of 2029.
- Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
